Harvard Bioscience Inc. (HBIO) is a reputed global developer, manufacturer, and marketer of a wide range of specialized products primarily scientific instruments used to accelerate drug discovery and research advancements in life science. The company is a key leader in the field of life sciences, having roots that extend back over a century to its foundation in 1901. The company has its head office in Holliston, Massachusetts and has its presence in more than 100 countries worldwide.
HBIO offers over 5,000 products in its portfolio to thousands of researchers in over 100 countries, operating under trusted brand names including Denville Scientific, Multi Channel Systems, Warner Instruments, and several others. These products find wide application in areas such as molecular, cellular, and physiological research.
Harvard Bioscience's commitment to scientific advancements is evident in its investment in Research & Development. Their operations are characterized by the development of state-of-the-art technologies and instruments to foster breakthroughs in the life sciences sector. The products they produce serve as essential laboratory tools, which enable critical research developments in regenerative medicine and drug discovery.
The company's goal is to leverage their technical and commercial expertise to enhance productivity and outcomes in laboratories worldwide. As such, they play a crucial role in driving scientific research and enabling discoveries that contribute to improving global health conditions.
HBIO’s strong financial performance is evident in its consistent revenue growth, driven by strategic acquisitions and organic growth. Over the years, the company has seen increased demand for their products and services due to the expansion of the life sciences industry and ongoing research initiatives globally.
HBIO is publicly traded on the NASDAQ Stock Market. It has shown resilience in the face of market fluctuations and continues to generate positive returns for its investors. In addition to its sound financial performance, Harvard Bioscience, Inc. also maintains a robust ethical stance, emphasizing corporate responsibility in its operations.
In summation, Harvard Bioscience Inc. holds a solid position in the life sciences industry due to its comprehensive product range, commitment to innovation, and a strong financial performance. Its significant contributions to scientific advancements and research emphasize the importance of its work in fostering understanding and progress in life sciences.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Harvard Bioscience insiders who bought shares in the last year have seen a 15% increase in their investment, adding US$4.1 million to the company's market value. The largest insider purchase was made by Independent Director William Snider for US$104,000 at a price below the current market value. While there have been no insider sales, the article suggests that higher insider ownership would provide more confidence, and no recent transactions have occurred in the last three months.
Insiders at Harvard Bioscience (NASDAQ:HBIO) who purchased shares in the last year have seen a positive return on their investment, with the stock climbing 15% and adding US$4.1 million to the company's market value. Their original US$202.4k purchase is now worth US$290.3k. While there have been no insider transactions in the last three months, the buying activity over the past year, particularly a US$104k purchase by Independent Director William Snider, suggests a degree of insider confidence, although insider ownership remains at 7.1%.
Benchmark has increased its price target for Harvard Bioscience Inc. (NASDAQ:HBIO) to $7.50 from $6.00, maintaining a Speculative Buy rating, following the company's strong second-quarter revenue of $22.7 million which surpassed guidance. The company also raised its full-year 2026 revenue growth guidance to 3%-5%. Despite this, analysts expect the company to not be profitable in fiscal 2026.
Benchmark has increased its price target for Harvard Bioscience (NASDAQ:HBIO) to $7.50 from $6.00, maintaining a Speculative Buy rating, after the company surpassed its second-quarter revenue guidance and consensus estimates. Harvard Bioscience also raised its full-year 2026 revenue growth outlook to 3-5% and reported strong demand across multiple product lines and regions. This positive outlook is supported by ongoing cost discipline and manufacturing consolidation efforts under Project Viking.
Harvard Bioscience (HBIO) reported its Q2 2026 financial results, showing a narrower-than-expected adjusted loss of $0.14 per share, beating analyst estimates. Revenue increased by 10.7% to $22.7 million. The company attributes this improvement to steady demand for its laboratory equipment and instruments, reflecting stabilization in the biotech research sector.
Harvard Bioscience (NASDAQ:HBIO) reported better-than-expected Q2 results, with adjusted EPS of -$0.14 and revenue of $22.7 million, exceeding analyst estimates. The company raised its full-year 2026 revenue guidance to 3%-5% YoY growth, citing strong commercial traction in its products. Despite a GAAP net loss, Harvard Bioscience maintained its adjusted EBITDA target and updated its gross margin outlook.
Harvard Bioscience (HBIO) reported an 11% increase in Q2 2026 revenue, reaching $22.7 million, despite a GAAP net loss of $2.9 million. The company also raised its full-year 2026 revenue guidance to 3% to 5% growth. Insider trading data shows multiple purchases of HBIO stock, and hedge funds have had mixed activity with some increasing and others decreasing their positions.